What's Going On With Moderna Stock Monday?
What's Going On With Moderna Stock Monday?
Moderna Inc (NASDAQ:MRNA) shares are trading higher. The company on Monday announced positive Phase 3 trial data for its combination vaccine against Influenza and COVID-19.
Moderna Inc(NASDAQ: MRNA)股價上漲。該公司週一宣佈了其抗流感和新冠疑似病例的聯合疫苗的積極第三階段試驗數據。
What Happened: Moderna said its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, met its primary endpoints after eliciting a higher immune response than the licensed comparator vaccines used in the trial.
發生了什麼：Moderna表示，mRNA-1083的第3期試驗，這是一種可調查的抗流感和新冠疑似病例的聯合疫苗，達到其主要終點，因爲它引出了比試驗中使用的許可比較疫苗更高的免疫反應。
Moderna's mRNA-1083 comprises components of mRNA-1010, the company's vaccine candidate for seasonal influenza, and mRNA-1283, its next-generation COVID-19 vaccine candidate.
Moderna的mRNA-1083包括mRNA-1010的組分，這是該公司的季節性流感疫苗候選者，以及其下一代COVID-19疫苗候選者mRNA-1283。
"Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses. Moderna is the only company with a positive Phase 3 flu and COVID combination vaccine," said Stéphane Bancel, CEO of Moderna.
“聯合疫苗有可能減輕呼吸道病毒對衛生系統和藥房的負擔，爲人們提供更方便的疫苗選擇，從而提高遵從性，並提供更強的應對季節性疾病的保護。Moderna是唯一一家獲得第三階段流感和新冠疫苗積極結果的公司，”Moderna的CEO Stephane Bancel說。
Moderna plans to present the Phase 3 clinical data for mRNA-1083 at an upcoming medical conference and submit it for publication. The company said it will engage with regulators about its next steps.
Moderna計劃在即將到來的醫學會議上展示mRNA-1083的第3期臨床數據並提交出版物。該公司表示，將與監管機構接洽其下一步工作的安排。
MRNA Price Action: Moderna shares were up 1.32% at $153 at the time of publication, according to Benzinga Pro.
MRNA股價行動：根據Benzinga Pro的數據，在發表時，Moderna股價上漲了1.32％，報153美元。
Photo: Shutterstock.
照片：shutterstock。
譯文內容由第三人軟體翻譯。